Androgen Receptor (AR) assay for longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow up.
AR is a key driver of prostate cancer growth and progression¹,². Although androgen deprivation therapy is standard of care, resistance frequently develops due to AR mutations, amplification, or overexpression, leading to metastatic castration-resistant prostate cancer (mCRPC)¹,². Monitoring AR status is therefore critical for evaluating therapeutic response and guiding patient selection in clinical trials².
How Can CelLBxHealth’s AR Assay Support Your Clinical Trial?
- Enable minimally invasive liquid biopsy assessment of AR
- Optimize patient selection
- Provide an early competitive advantage by understanding therapeutic response sooner
- Longitudinal monitoring for changes in AR status on a phenotypic variety of CTCs
- Highly accurate, repeatable, and precise AR CTC results
Example assay outputs
Image D (spiking study)
Untreated AR+ LNCaP cells (top) show strong AR signal, which decreases with inhibitor treatment (middle). AR– PC-3 cells (bottom) show no AR signal, confirming specificity. Colours: DNA blue (DAPI), AR orange (Cy3), epithelial green (FITC), mesenchymal purple (Cy7), blood lineage white (Cy5).
Image E (patient CTC cluster)
AR expression detected in an EMT CTC cluster with clear nuclear AR positivity. Colours: DNA blue, AR orange, epithelial green, mesenchymal purple.
Image F (patient CTC cluster)
Image of mesenchymal CTC cluster showing nuclear (Cy3:Top), and cytoplasmic (Cy3:Bottom) AR positivity.
Image G (patient CTC cluster, negative)
Mesenchymal CTCs with no AR expression, showing absence of AR signal.
For Research Use Only. Not For Use in Diagnostic Procedures.
References
1. Huang, J., et al. (2022). Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective. Frontiers in oncology, 12, 865350. https://doi.org/10.3389/fonc.2022.865350.
2. Kwan EM, Wyatt AW. Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. The Prostate. 2022; 82: S25-S36. doi:10.1002/pros.24356.